Bigbear Pharmaceutical·Medication Guide

• How to Store Deucravacitinib

  Store at room temperature between 68°F and 77°F (20°C and 25°C).Keep all medications away from children and pets.【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 232

• How to Take Deucravacitinib

  Take deucravacitinib tablets precisely as instructed by your healthcare provider.This medication should be taken once daily.Tablets may be taken with ···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 201

• Deucravacitinib Price in the US vs. Overseas: How to Access Affordable Generic Options

  The price of deuterocelexitinib is affected by region, dosage, and health insurance policies. Specific costs should be confirmed with your local hospi···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 211

• How Much Does Deucravacitinib Cost with Insurance? Out-of-Pocket Costs & Copay Assistance in 202

  Deuterocactinib is an oral targeted therapy primarily used to treat moderate to severe plaque psoriasis and other immune-related diseases. Its price f···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 219

• Promacta vs. Generic Deucravacitinib 2026: Cost Comparison, Savings, and What You Need to Know

  The current domestic price of deuterocelexitinib (14 tablets) is approximately 4300-4800 RMB per box (14 tablets). The specific price may fluctuate sl···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 180

• Deucravacitinib Achieves Success in Phase 3 Clinical Trial for Plaque Psoriasis!

  Bristol-Myers Squibb (BMS) recently announced that the pivotal Phase 3 POETYK PSO-1 study evaluating the novel anti-inflammatory drug deucravacitinib ···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 235

• New Drug for Moderate to Severe Plaque Psoriasis in Adults! US FDA Approves Sotyktu (deucravacitinib

  On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 192

• New Drug for Moderate to Severe Plaque Psoriasis in Adults! US FDA Approves Sotyktu (deucravacitinib

  On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 209

• Sotyktu (deucravacitinib) Demonstrates Good Safety and Tolerability in Treating Moderate to Severe P

  Bristol-Myers Squibb announced on September 9, 2022, that the U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the t···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 188

• Sotyktu (deucravacitinib) has been approved by the European Commission

  The European Commission (EC) recently approved Bristol-Myers Squibb's Sotyktu (deucravacitinib) as a once-daily oral tablet for the treatment of a···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 231

• Sotyktu, the first TYK2 inhibitor for treating active psoriatic arthritis in adults, has been approv

  Bristol-Myers Squibb recently announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the treatment of act···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 161

• Can TUKYSA (tucatinib) treat metastatic HER2-positive breast cancer?

  Seattle Genetics recently announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capec···【Read More】

  Update: 2026-03-27Source: Haiou HealthViews: 166

• Can TUKYSA (tucatinib) treat metastatic HER2-positive breast cancer?

  Seattle Genetics recently announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capec···【Read More】

  Update: 2026-03-27Source: Haiou HealthViews: 165

• ​What are the side effects of Tukysa (Tucatinib) for treating breast cancer patients?

  On April 17, 2020, the U.S. Food and Drug Administration (FDA) approved the new breast cancer drug Tukysa in combination with trastuzumab (Herceptin) ···【Read More】

  Update: 2026-03-27Source: Haiou HealthViews: 198

• Tukysa (tucatinib) in combination with trastuzumab demonstrates antitumor activity in HER2-positive

  On July 2, 2022, Seagen announced the full results of the pivotal Phase 2 MOUNTAINEER trial, demonstrating that tucatinib (trademark: TUKYSA) in combi···【Read More】

  Update: 2026-03-27Source: Haiou HealthViews: 169